No Data
Novartis On Pace for Record High Close -- Data Talk
Novartis, Lindy Biosciences Sign Deal for Subcutaneous Injection Technology
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
Express News | Novartis' Phase 3 V MONO Study For Twice-yearly Leqvio (Inclisiran) Met Its Primary Endpoints Showing Leqvio Monotherapy Lowered Low-density Lipoprotein Cholesterol Versus Placebo And Ezetimibe In Patients Who Were At Low Or Moderate Risk Of...
Novartis' Twice-yearly Drug Lowers Cholesterol in Late-stage Study
Cigna PBM Express Scripts to Remove Humira From Many Formularies